UNSPSC 51434945: Hydrochlorothiazide/olmesartan

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434945 Hydrochlorothiazide/olmesartan is a Commodity code representing individual prescription medications—in this case, a branded antihypertensive combination therapy—that state and local health care systems, public safety agencies, and health departments procure through direct purchase, cooperative purchasing agreements, and pharmacy benefit programs. State and local governments buy these medications for emergency medical services, public health clinics, institutional pharmacies, and employee health benefit plans. Issuing bodies include city fire and emergency services departments (like Tampa Fire Rescue), state health and human services commissions managing Medicaid and public employee pharmacy benefits, and multistate cooperative purchasing alliances that aggregate demand across dozens of states and localities. The sourcing model varies widely: some jurisdictions buy through traditional sealed-bid solicitations against specific medication line items; others participate in cooperative purchasing RFPs that establish framework agreements with pharmaceutical manufacturers and require distribution through authorized wholesalers; still others are exploring direct-to-manufacturer contracting models to reduce pharmacy benefit manager middlemen and negotiate net pricing.

Recent activity spans Florida, Texas, Minnesota, and Oregon. The City of Tampa issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications—including epinephrine, labetalol, adenosine, and diltiazem—with delivery required within ten days and a one-year contract term; estimated value was $40,000, with a 5 percent bid discount available for Small Local Business Enterprise participation. The Texas Health and Human Services Commission posted a Request for Information in April 2026 to explore direct-to-manufacturer prescription fulfillment strategies outside traditional pharmacy benefit manager and group purchasing organization channels, signaling movement toward alternative contracting models in state pharmacy benefit programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026, and two-year terms; evaluation weighted price competitiveness at 75 percent and required compliance with cGMP, DSCSA, FDA requirements, and $5 million commercial general liability insurance. The code sees active procurement across emergency medical services, Medicaid/public health benefit programs, and cooperative purchasing platforms, with pressure toward cost competition and manufacturing compliance.